ORKA
Oruka Therapeutics, Inc. NASDAQ Listed Aug 8, 1997$64.05
Mkt Cap $2.4B
52w Low $8.91
67.2% of range
52w High $91.00
50d MA $51.83
200d MA $31.46
P/E (TTM)
-27.1x
EV/EBITDA
-11.0x
P/B
6.0x
Debt/Equity
0.0x
ROE
-22.3%
P/FCF
-15.6x
RSI (14)
—
ATR (14)
—
Beta
-0.61
50d MA
$51.83
200d MA
$31.46
Avg Volume
906.0K
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
221 Crescent Street Building 23, Suite 105 · Menlo Park, MA 94025 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.61 | -0.45 | +26.2% | 31.99 | +2.7% | +25.0% | +30.5% | +29.1% | +27.5% | +21.4% | — |
| Nov 12, 2025 | AMC | -0.56 | -0.55 | +1.8% | 28.30 | +5.3% | -6.8% | -4.3% | -0.2% | -3.0% | -0.1% | — |
| Aug 11, 2025 | AMC | -0.48 | -0.46 | +4.2% | 13.05 | +1.3% | +6.9% | +17.5% | +14.9% | +17.8% | +16.9% | — |
| May 14, 2025 | AMC | -0.57 | -0.40 | +29.8% | 9.71 | +8.0% | -2.6% | +3.6% | +6.2% | +9.4% | +9.0% | — |
| Mar 6, 2025 | AMC | -0.68 | -0.49 | +27.9% | 10.07 | -0.9% | +3.9% | +8.6% | +9.8% | +14.7% | +10.6% | — |
| Nov 13, 2024 | AMC | -0.40 | -1.46 | -265.0% | 25.65 | -3.0% | -6.4% | -6.3% | -17.6% | -13.1% | -13.5% | — |
| Aug 27, 2024 | AMC | — | -1.53 | — | 46.56 | -0.8% | -10.1% | -35.6% | -38.1% | -45.2% | -39.9% | — |
| Apr 25, 2024 | AMC | — | -0.14 | — | 41.76 | +5.7% | +2.9% | -1.4% | +0.3% | -6.6% | -6.3% | — |
| Dec 31, 2023 | AMC | — | -0.08 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.10 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -0.10 | — | 24.36 | -1.0% | +0.5% | +0.0% | +1.0% | +1.5% | +0.5% | — |
| Mar 31, 2023 | AMC | — | -0.09 | — | 23.88 | -0.5% | -2.0% | +0.0% | -2.0% | -1.0% | +1.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | Barclays | Maintains | Overweight → Overweight | — | $76.39 | $78.21 | +2.4% | -3.1% | -10.9% | -10.4% | -18.1% | -13.0% |
| Apr 28 | UBS | Maintains | Buy → Buy | — | $76.39 | $78.21 | +2.4% | -3.1% | -10.9% | -10.4% | -18.1% | -13.0% |
| Apr 27 | BTIG | Maintains | Buy → Buy | — | $69.03 | $90.02 | +30.4% | +10.7% | +7.2% | -1.3% | -0.9% | -9.3% |
| Apr 15 | Wedbush | Maintains | Outperform → Outperform | — | $67.06 | $67.45 | +0.6% | -2.3% | +0.0% | +2.8% | +2.7% | +2.9% |
| Apr 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $59.58 | $60.16 | +1.0% | +3.0% | +12.6% | +10.0% | +12.6% | +15.7% |
| Apr 13 | Guggenheim | Maintains | Buy → Buy | — | $59.58 | $60.16 | +1.0% | +3.0% | +12.6% | +10.0% | +12.6% | +15.7% |
| Apr 13 | BTIG | Maintains | Buy → Buy | — | $59.58 | $60.16 | +1.0% | +3.0% | +12.6% | +10.0% | +12.6% | +15.7% |
| Apr 9 | Guggenheim | Maintains | Buy → Buy | — | $62.01 | $62.60 | +1.0% | +2.6% | -3.9% | -1.0% | +8.1% | +5.7% |
| Apr 7 | Barclays | Maintains | Overweight → Overweight | — | $56.37 | $56.28 | -0.2% | +7.5% | +10.0% | +12.8% | +5.7% | +8.9% |
| Apr 6 | Guggenheim | Maintains | Buy → Buy | — | $53.31 | $55.00 | +3.2% | +5.7% | +13.7% | +16.3% | +19.3% | +11.8% |
| Apr 6 | UBS | Maintains | Buy → Buy | — | $53.31 | $55.00 | +3.2% | +5.7% | +13.7% | +16.3% | +19.3% | +11.8% |
| Mar 16 | Leerink Partners | Maintains | Outperform → Outperform | — | $40.00 | $41.30 | +3.2% | +4.4% | +3.3% | +2.0% | -3.0% | -2.7% |
| Mar 13 | BTIG | Maintains | Buy → Buy | — | $31.99 | $32.84 | +2.7% | +25.0% | +30.5% | +29.1% | +27.5% | +21.4% |
| Mar 13 | Guggenheim | Maintains | Buy → Buy | — | $31.99 | $32.84 | +2.7% | +25.0% | +30.5% | +29.1% | +27.5% | +21.4% |
| Mar 13 | Barclays | Maintains | Overweight → Overweight | — | $31.99 | $32.84 | +2.7% | +25.0% | +30.5% | +29.1% | +27.5% | +21.4% |
| Mar 13 | Wedbush | Maintains | Outperform → Outperform | — | $31.99 | $32.84 | +2.7% | +25.0% | +30.5% | +29.1% | +27.5% | +21.4% |
| Mar 13 | Stifel | Maintains | Buy → Buy | — | $31.99 | $32.84 | +2.7% | +25.0% | +30.5% | +29.1% | +27.5% | +21.4% |
| Jan 13 | Wedbush | Maintains | Outperform → Outperform | — | $30.69 | $31.56 | +2.8% | +2.1% | +4.3% | +5.9% | +8.8% | +8.3% |
| Jan 12 | BTIG | Maintains | Buy → Buy | — | $27.86 | $27.74 | -0.4% | +10.2% | +12.5% | +14.9% | +16.7% | +19.9% |
| Nov 13 | BTIG | Maintains | Buy → Buy | — | $28.30 | $29.79 | +5.3% | -6.8% | -4.3% | -0.2% | -3.0% | -0.1% |
| Oct 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.25 | $27.91 | +2.4% | +1.7% | +0.7% | +1.3% | +3.2% | +3.4% |
| Sep 29 | BTIG | Maintains | Buy → Buy | — | $15.20 | $16.75 | +10.2% | +26.9% | +26.5% | +22.5% | +26.2% | +30.2% |
| Sep 17 | Clear Street | Maintains | Buy → Buy | — | $14.90 | $17.72 | +18.9% | +8.8% | +11.3% | +4.4% | +15.1% | +4.4% |
| Sep 17 | BTIG | Maintains | Buy → Buy | — | $14.90 | $17.72 | +18.9% | +8.8% | +11.3% | +4.4% | +15.1% | +4.4% |
| Aug 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.37 | $15.60 | +1.5% | -0.8% | -5.3% | -6.3% | -3.8% | +0.5% |
| Jul 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.06 | $14.13 | +0.5% | +3.4% | +1.2% | +1.4% | -0.4% | -2.3% |
| May 15 | Wedbush | Maintains | Outperform → Outperform | — | $9.71 | $10.49 | +8.0% | -2.6% | +3.6% | +6.2% | +9.4% | +9.0% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.08 | $13.01 | -0.5% | -12.8% | -16.6% | -16.1% | -9.3% | -12.6% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.76 | $20.31 | -2.2% | -2.2% | +1.2% | +1.8% | -3.8% | -8.4% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.75 | $20.71 | -0.2% | -10.8% | -9.9% | -2.4% | +4.7% | +1.0% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.88 | $28.85 | -0.1% | -3.0% | -5.9% | -6.7% | -7.6% | -4.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Sandler Laura LeeOff | Chief Operating Officer | Sell | 100 | $68.48 | $7K | 236,984 | +6.20% | +3.21% |
| May 1, 2026 | Sandler Laura LeeOff | Chief Operating Officer | Sell | 200 | $67.16 | $13K | 237,084 | +6.20% | +3.21% |
| May 1, 2026 | Sandler Laura LeeOff | Chief Operating Officer | Sell | 400 | $66.06 | $26K | 237,284 | +6.20% | +3.21% |
| May 1, 2026 | Sandler Laura LeeOff | Chief Operating Officer | Sell | 300 | $65.10 | $20K | 237,684 | +6.20% | +3.21% |
| May 1, 2026 | Sandler Laura LeeOff | Chief Operating Officer | Sell | 1,800 | $64.15 | $115K | 237,984 | +6.20% | +3.21% |
| May 1, 2026 | Sandler Laura LeeOff | Chief Operating Officer | Sell | 2,200 | $62.58 | $138K | 239,784 | +6.20% | +3.21% |
Data updated apr 26, 2026 5:53pm
· Source: massive.com